You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,587,239


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,587,239
Title:Methods of identifying and treating glioblastoma
Abstract: The invention encompasses methods and kits used in the detection of invasive glioblastoma based upon the expression of NHERF-1. The methods and kits also allow prediction of disease outcome as well as therapeutic outcome.
Inventor(s): Kislin; Kerri L. (Phoenix, AZ), Berens; Michael Edward (Phoenix, AZ)
Assignee: The Translational Genomics Research Institute (Phoenix, AZ)
Application Number:14/629,431
Patent Claims:1. A method of sensitizing a subject diagnosed with invasive cancer to a therapeutic that targets non-migrating cells, the method comprising the step of administering to the subject a NHERF1 (SEQ ID NO:1 or SEQ ID NO:2) inhibitor wherein the inhibition of NHERF1 switches invasive cancer cells in the subject to non-migrating cancer cells that are sensitive to a therapeutic that targets the non-migrating cells.

2. The method of claim 1, wherein the therapeutic is selected from the group consisting of Temozolomide and bevacizumab.

3. The method of claim 1, wherein the NHERF1 inhibitor is an siRNA against the nucleotide sequence of SEQ ID NO:1.

4. The method of claim 3, wherein the NHERF1 inhibitor is selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.

5. The method of claim 1, wherein the invasive cancer is selected from the group consisting of glioblastoma, breast cancer, and hepatocellular carcinoma.

6. A method of treating invasive cancer in a subject, the method comprising the steps of: administering to the subject a NHERF1 (SEQ ID NO:1 or SEQ ID NO:2) inhibitor that switches invasive cancer cells to non-migrating cancer cells; and administering a chemotherapeutic agent.

7. The method of claim 6, wherein the NHERF1 inhibitor is an siRNA against the nucleotide sequence of SEQ ID NO:1.

8. The method of claim 7, wherein the NHERF1 inhibitor is selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.

9. The method of claim 6, wherein the chemotherapeutic agent is selected from the group consisting of Temozolomide and bevacizumab.

10. The method of claim 6, wherein the invasive cancer is selected from the group consisting of glioblastoma, breast cancer, and hepatocellular carcinoma.

11. A method of inhibiting the migration of cancer cells in a subject, the method comprising the step of administering to the subject a NHERF1 (SEQ ID NO:1 or SEQ ID NO:2) inhibitor.

12. The method of claim 11, wherein the NHERF1 inhibitor 1 is an siRNA against the nucleotide sequence of SEQ ID NO:1.

13. The method of claim 11, wherein the NHERF1 inhibitor is selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.

14. The method of claim 11, wherein the cancer cells is selected from the group consisting of glioblastoma, breast cancer, and hepatocellular carcinoma.

15. The method of claim 9, wherein inhibiting the migration of cancer cells also sensitizes the cancer cells to a chemotherapeutic agent.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.